These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 11739153)

  • 1. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment.
    Giuliani N; Bataille R; Mancini C; Lazzaretti M; Barillé S
    Blood; 2001 Dec; 98(13):3527-33. PubMed ID: 11739153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
    Huang L; Xu J; Wood DJ; Zheng MH
    Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
    Grimaud E; Soubigou L; Couillaud S; Coipeau P; Moreau A; Passuti N; Gouin F; Redini F; Heymann D
    Am J Pathol; 2003 Nov; 163(5):2021-31. PubMed ID: 14578201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages.
    Itonaga I; Sabokbar A; Murray DW; Athanasou NA
    Ann Rheum Dis; 2000 Jan; 59(1):26-31. PubMed ID: 10627423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.
    Kostenuik PJ; Shalhoub V
    Curr Pharm Des; 2001 May; 7(8):613-35. PubMed ID: 11375772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture.
    Komine M; Kukita A; Kukita T; Ogata Y; Hotokebuchi T; Kohashi O
    Bone; 2001 May; 28(5):474-83. PubMed ID: 11344046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.
    Giuliani N; Colla S; Sala R; Moroni M; Lazzaretti M; La Monica S; Bonomini S; Hojden M; Sammarelli G; Barillè S; Bataille R; Rizzoli V
    Blood; 2002 Dec; 100(13):4615-21. PubMed ID: 12393684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.
    Gori F; Hofbauer LC; Dunstan CR; Spelsberg TC; Khosla S; Riggs BL
    Endocrinology; 2000 Dec; 141(12):4768-76. PubMed ID: 11108292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
    Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
    J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
    Cheung J; Mak YT; Papaioannou S; Evans BA; Fogelman I; Hampson G
    J Endocrinol; 2003 Jun; 177(3):423-33. PubMed ID: 12773123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells].
    Su X; Liao EY; Peng J; Wu XP
    Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):800-3. PubMed ID: 14636471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
    Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoprotegerin and osteoprotegerin ligand expression during human marrow stromal cell differentiation and their effect on osteoclast formation.
    Yang L; Hai Y; Zhou JL
    Chin Med J (Engl); 2011 Jul; 124(13):2033-7. PubMed ID: 22088466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
    Burgess TL; Qian Y; Kaufman S; Ring BD; Van G; Capparelli C; Kelley M; Hsu H; Boyle WJ; Dunstan CR; Hu S; Lacey DL
    J Cell Biol; 1999 May; 145(3):527-38. PubMed ID: 10225954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANK ligand and osteoprotegerin in myeloma bone disease.
    Sezer O; Heider U; Zavrski I; Kühne CA; Hofbauer LC
    Blood; 2003 Mar; 101(6):2094-8. PubMed ID: 12424190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
    Lee SK; Lorenzo JA
    Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.